Pringsheim T, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.
Article
Google Scholar
Prince M, et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimer’s Research and Therapy. 2016. https://doi.org/10.1186/s13195-016-0188-8.
Article
Google Scholar
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.
Article
Google Scholar
Heneka MT, et al. Neuroinflammation in Alzheimer’s disease. The Lancet Neurology. 2015;14(4):388–405.
Article
CAS
Google Scholar
Breitner J. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16(4):523–30.
Article
CAS
Google Scholar
Barber Pérez P, et al. Evolución del consumo y gasto farmacéutico público de anti-inflamatorios no esteroideos (aines) en el período 2001–2005. Revista Costarricense de Salud Pública. 2007;16(31):19–26.
Google Scholar
Lindsay CB, et al. Andrographolide reduces neuroinflammation and oxidative stress in aged Octodon degus. Mol Neurobiol. 2019;57(2):1131–45.
Article
Google Scholar
Wang Y, et al. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett. 2011;487(1):70–2.
Article
CAS
Google Scholar
Koenigsknecht-Talboo J, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008;28(52):14156–64.
Article
CAS
Google Scholar
Akiyama H, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421.
Article
CAS
Google Scholar
Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biol. 2011. https://doi.org/10.1007/s11515-011-1123-9.
Article
Google Scholar
Kalden JR. What is inflammation? Eur Heart J. 1987;8(suppl J):1–5.
Article
Google Scholar
Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3–23.
Article
Google Scholar
Fabbri LM, et al. Physiologic consequences of long-term inflammation. Am J Respir Crit Care Med. 1998;157(5):S195–8.
Article
CAS
Google Scholar
Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-460S.
Article
CAS
Google Scholar
Chung HY, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18–30.
Article
CAS
Google Scholar
Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1–12.
Article
CAS
Google Scholar
Carson MJ, Thrash JC, Walter B. The cellular response in neuroinflammation: the role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin Neurosci Res. 2006;6(5):237–45.
Article
CAS
Google Scholar
Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010;7(4):354–65.
Article
CAS
Google Scholar
Lyman M, et al. Neuroinflammation: the role and consequences. Neurosci Res. 2014;79:1–12.
Article
CAS
Google Scholar
Haskó G, et al. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci. 2005;26(10):511–6.
Article
Google Scholar
Aschner M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology. 1998;19(2):269–81.
CAS
Google Scholar
Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurotherapeutics. 2010;7(4):366–77.
Article
CAS
Google Scholar
Kaur D, Sharma V, Deshmukh R. Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease. Inflammopharmacology. 2019;27(4):663–77.
Article
Google Scholar
Serrano-Pozo A, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011;179(3):1373–1373.
Article
Google Scholar
Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12(1):1–16.
Article
Google Scholar
Bachiller S, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci. 2018. https://doi.org/10.3389/fncel.2018.00488.
Article
Google Scholar
Nordengen K, et al. Glial activation and inflammation along the Alzheimer’s disease continuum. J Neuroinflammation. 2019. https://doi.org/10.1186/s12974-019-1399-2.
Article
Google Scholar
Chun H, et al. Elucidating the interactive roles of glia in Alzheimer’s disease using established and newly developed experimental models. Front Neurol. 2018;9(SEP):797–797.
Article
Google Scholar
Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Investig. 2017;127(9):3240–3240.
Article
Google Scholar
Bolmont T, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28(16):4283–4283.
Article
CAS
Google Scholar
Navarro V, et al. Microglia in Alzheimer’s disease: activated, dysfunctional or degenerative. Front Aging Neurosci. 2018. https://doi.org/10.3389/fnagi.2018.00140.
Article
Google Scholar
Herber DL, et al. Microglial activation is required for Aβ clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol. 2007;2(2):222–31.
Article
Google Scholar
Rojo LE, et al. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res. 2008;39(1):1–16.
Article
CAS
Google Scholar
Smith JA, et al. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87(1):10–20.
Article
CAS
Google Scholar
He P, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer’s mice. J Cell Biol. 2007;178(5):829–829.
Article
CAS
Google Scholar
Siracusa R, Fusco R, Cuzzocrea S. Astrocytes: role and functions in brain pathologies. Front Pharmacol. 2019. https://doi.org/10.3389/fphar.2019.01114.
Article
Google Scholar
Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014;94(4):1077–98.
Article
Google Scholar
Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229–37.
Article
CAS
Google Scholar
Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer’s disease. Open Biol. 2017. https://doi.org/10.1098/rsob.170228.
Article
Google Scholar
Wyssenbach A, et al. Amyloid β-induced astrogliosis is mediated by β1-integrin via NADPH oxidase 2 in Alzheimer’s disease. Aging Cell. 2016;15(6):1140–52.
Article
CAS
Google Scholar
Han X, et al. Astrocyte senescence and Alzheimer’s disease: a review. Front Aging Neurosci. 2020. https://doi.org/10.3389/fnagi.2020.00148.
Article
Google Scholar
Verkhratsky A, et al. Astrocytes in Alzheimer’s disease. Neurotherapeutics. 2010;7(4):399–412.
Article
CAS
Google Scholar
Pajarillo E, et al. The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: potential targets for neurotherapeutics. Neuropharmacology. 2019;161:107559–107559.
Article
CAS
Google Scholar
Simpson JE, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31(4):578–90.
Article
CAS
Google Scholar
Kinney JW, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dementia Transl Res Clin Interv. 2018;4:575–575.
Article
Google Scholar
Lanfranco GR, et al. Evaluación de la enfermedad de Alzheimer en etapa temprana: biomarcadores y pruebas neuropsicológicas. Rev Med Chil. 2012;140(9):1191–200.
Article
Google Scholar
Pascoal TA, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592–9.
Article
CAS
Google Scholar
Floden AM, Li S, Combs CK. β-Amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors. J Neurosci. 2005;25(10):2566–2566.
Article
CAS
Google Scholar
Streit WJ, Mrak RE, Griffin WST. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation. 2004;1:14–14.
Article
Google Scholar
Rogers J, Lue L-F. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer’s disease. Neurochem Int. 2001;39(5–6):333–40.
Article
CAS
Google Scholar
Liu S, et al. TLR2 is a primary receptor for alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J Immunol. 2012;188(3):1098–107.
Article
CAS
Google Scholar
Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2015;53(2):1181–94.
Article
Google Scholar
Fiebich BL, et al. Role of microglia TLRs in neurodegeneration. Front Cell Neurosci. 2018. https://doi.org/10.3389/fncel.2018.00329.
Article
Google Scholar
Li C, et al. Inhibitory effects of betulinic acid on LPS-induced neuroinflammation involve M2 microglial polarization via CaMKKβ-dependent AMPK activation. Front Mol Neurosci. 2018;11:98–98.
Article
Google Scholar
Chen C, et al. Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis. Acta Pharmacol Sin. 2014;35(11):1428–38.
Article
CAS
Google Scholar
Escribano L, et al. Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010;35(7):1593–604.
Article
CAS
Google Scholar
Yamanaka M, et al. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci. 2012;32(48):17321–31.
Article
CAS
Google Scholar
Ji J, et al. Antagonizing peroxisome proliferator-activated receptor γ facilitates M1-to-M2 shift of microglia by enhancing autophagy via the LKB1-AMPK signaling pathway. Aging Cell. 2018;17(4):e12774–e12774.
Article
Google Scholar
Yao K, Zu H-B. Microglial polarization: novel therapeutic mechanism against Alzheimer’s disease. Inflammopharmacology. 2019;28(1):95–110.
Article
Google Scholar
Ferretti MT, et al. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer’s disease. Neurobiol Aging. 2012;33(7):1329–42.
Article
CAS
Google Scholar
Paranjape GS, et al. Isolated amyloid-β(1–42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. ACS Chem Neurosci. 2012;3(4):302–302.
Article
CAS
Google Scholar
Darocha-Souto B, et al. Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol. 2011;70(5):360–76.
Article
CAS
Google Scholar
Crouse NR, et al. Oligomeric amyloid-β(1–42) induces THP-1 human monocyte adhesion and maturation. Brain Res. 2009;1254:109–19.
Article
CAS
Google Scholar
Arbel-Ornath M, et al. Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegeneration. 2017. https://doi.org/10.1186/s13024-017-0169-9.
Article
Google Scholar
Calvo-Rodriguez M, et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nat Commun. 2020;11(1):1–17.
Article
Google Scholar
Guan PP, et al. Calcium ions aggravate Alzheimer’s disease through the aberrant activation of neuronal networks, leading to synaptic and cognitive deficits. Front Mol Neurosci. 2021. https://doi.org/10.3389/fnmol.2021.757515.
Article
Google Scholar
Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94(1):55–68.
Article
CAS
Google Scholar
Wan W, et al. Aβ1–42 oligomer-induced leakage in an in vitro blood–brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem. 2015;134(2):382–93.
Article
CAS
Google Scholar
Sturchler E, et al. Site-specific blockade of RAGE-Vd prevents amyloid-β oligomer neurotoxicity. J Neurosci. 2008;28(20):5149–5149.
Article
CAS
Google Scholar
Deane R, et al. A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease. J Clin Investig. 2012;122(4):1377–92.
Article
CAS
Google Scholar
Ferrera D, et al. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage. Neurobiol Aging. 2014;35(11):2444–57.
Article
CAS
Google Scholar
Chidambaram H, Das R, Chinnathambi S. Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation. Cell Biosci. 2020;10:109–109.
Article
CAS
Google Scholar
Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer’s disease. Mount Sinai J Med. 2010;77(1):50–8.
Article
Google Scholar
Laurent C, Buée L, Blum D. Tau and neuroinflammation: what impact for Alzheimer’s disease and tauopathies? Biomed J. 2018;41(1):21–33.
Article
Google Scholar
Morales G, Farías IG, Maccioni RB. La neuroinflamación como factor detonante del desarrollo de la enfermedad de Alzheimer. Rev Chil Neuropsiquiatr. 2010. https://doi.org/10.4067/S0717-92272010000200007.
Article
Google Scholar
Quintanilla RA, et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004. https://doi.org/10.1016/j.yexcr.2004.01.002.
Article
Google Scholar
Pawelec P, et al. The impact of the CX3CL1/CX3CR1 axis in neurological disorders. Cells. 2020. https://doi.org/10.3390/cells9102277.
Article
Google Scholar
Bolós M, et al. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol Neurodegener. 2017;12(1):1–14.
Article
Google Scholar
Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138(6):1738–1738.
Article
Google Scholar
Nilson AN, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J Alzheimers Dis. 2017;55(3):1083–99.
Article
CAS
Google Scholar
Gaikwad S, et al. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia. Cell Rep. 2021;36(3):109419–109419.
Article
CAS
Google Scholar
Gupta P, et al. Tau oligomers trigger inflammation in the eyes of the Alzhiemer’s disease mouse models. Invest Ophthalmol Vis Sci. 2015;56(7):855–855.
Google Scholar
Das R, Balmik AA, Chinnathambi S. Phagocytosis of full-length Tau oligomers by actin-remodeling of activated microglia. J Neuroinflammation. 2020;17(1):1–15.
Article
Google Scholar
Sasaki Y, et al. Iba1 is an actin-cross-linking protein in macrophages/microglia. Biochem Biophys Res Commun. 2001;286(2):292–7.
Article
CAS
Google Scholar
Deming Y, et al. Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? HHS public access. Expert Opin Ther Targets. 2018;22(7):587–98.
Article
CAS
Google Scholar
Atagi Y, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290(43):26043–50.
Article
CAS
Google Scholar
Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem. 2015;290(43):26033–42.
Article
CAS
Google Scholar
Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71.
Article
CAS
Google Scholar
Yeh FL, et al. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91(2):328–40.
Article
CAS
Google Scholar
Bekris LM, et al. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. J Neuroimmunol. 2018;319:19–27.
Article
CAS
Google Scholar
Neumann H, Takahashi K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol. 2007;184(1–2):92–9.
Article
CAS
Google Scholar
Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):495–8.
Article
CAS
Google Scholar
Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2014;11:48–48.
Article
Google Scholar
Zhao Y, et al. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron. 2018;97(5):1023-1031.e7.
Article
CAS
Google Scholar
Guerreiro R, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.
Article
CAS
Google Scholar
Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16.
Article
CAS
Google Scholar
Zheng H, et al. TREM2 promotes microglial survival by activating Wnt/β-catenin pathway. J Neurosci. 2017;37(7):1772–84.
Article
CAS
Google Scholar
Reitz C, Mayeux R. TREM2 and Neurodegenerative Disease. N Engl J Med. 2013;369(16):1564–70.
Article
CAS
Google Scholar
Jadhav VS, et al. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol Neurodegener. 2020;15(1):62–62.
Article
CAS
Google Scholar
Ulrich JD, Holtzman DM. TREM2 function in Alzheimer’s disease and neurodegeneration. ACS Chem Neurosci. 2016;7(4):420–7.
Article
CAS
Google Scholar
Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–75.
Article
CAS
Google Scholar
Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer’s disease. J Neurosci. 2017;37(3):637–47.
Article
CAS
Google Scholar
Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212(3):287–95.
Article
CAS
Google Scholar
Kober DL, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5:e20391–e20391.
Article
Google Scholar
Bemiller SM, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017. https://doi.org/10.1186/s13024-017-0216-6.
Article
Google Scholar
Jiang T, et al. TREM2 ameliorates neuronal tau pathology through suppression of microglial inflammatory response. Inflammation. 2018;41(3):811–23.
Article
CAS
Google Scholar
Leyns CEG, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci USA. 2017;114(43):11524–9.
Article
CAS
Google Scholar
Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523–7.
Article
Google Scholar
Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–39.
Article
CAS
Google Scholar
Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.
Article
CAS
Google Scholar
Komatsu M, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880–4.
Article
CAS
Google Scholar
Gold M, El Khoury J. β-amyloid, microglia, and the inflammasome in Alzheimer’s disease. Semin Immunopathol. 2015;37(6):607–11.
Article
CAS
Google Scholar
Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170(4):649-663.e13.
Article
CAS
Google Scholar
Zhao L, Alzheimer A. CD33 in Alzheimer’s disease—biology, pathogenesis, and therapeutics: a mini-review. Gerontology. 2019;65(4):323–31.
Article
CAS
Google Scholar
Griciuc A, Tanzi RE. The role of innate immune genes in Alzheimer’s disease. Curr Opin Neurol. 2021;34(2):228–228.
Article
CAS
Google Scholar
Griciuc A, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–631.
Article
CAS
Google Scholar
Magno L, et al. Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimer’s Res Ther. 2019;11(1):1–11.
Article
Google Scholar
Tsai AP, et al. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease. Genome Medicine. 2022;14(1):1–13.
Article
Google Scholar
Jing H, et al. INPP5D rs35349669 polymorphism with late-onset Alzheimer’s disease: a replication study and meta-analysis. Oncotarget. 2016;7(43):69225–69225.
Article
Google Scholar
Tsai AP, et al. INPP5D expression is associated with risk for Alzheimer’s disease and induced by plaque-associated microglia. Neurobiol Dis. 2021;153:105303–105303.
Article
CAS
Google Scholar
Taipa R, et al. Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post mortem study. Neuropathol Appl Neurobiol. 2018;44(3):298–313.
Article
CAS
Google Scholar
Ferrari-Souza JP, et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Mol Psychiatry. 2022;2022:1–9.
Google Scholar
Ingelsson M, et al. Early A accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925–31.
Article
CAS
Google Scholar
Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503–8.
Article
CAS
Google Scholar
Tan ZS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology. 2007;68(22):1902–8.
Article
CAS
Google Scholar
Chang R, Yee K-L, Sumbria RK. Tumor necrosis factor α inhibition for Alzheimer’s disease. J Cent Nerv Syst Dis. 2017;9:117957351770927–117957351770927.
Article
Google Scholar
Kamer AR, et al. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J Neuroimmunol. 2009;216(1–2):92–7.
Article
CAS
Google Scholar
Tarkowski E, et al. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull. 2003;61(3):255–60.
Article
CAS
Google Scholar
Álvarez A, et al. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging. 2007;28(4):533–6.
Article
Google Scholar
Medeiros R, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci. 2007;27(20):5394–404.
Article
CAS
Google Scholar
Jones SV, Kounatidis I. Nuclear factor-kappa B and Alzheimer disease, unifying genetic and environmental risk factors from cell to humans. Front Immunol. 2017;8(DEC):1805–1805.
Article
Google Scholar
Kaltschmidt B, et al. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA. 1997;94(6):2642–7.
Article
CAS
Google Scholar
Mattson MP, Camandola S. NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Investig. 2001;107(3):247–247.
Article
CAS
Google Scholar
Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388(6645):878–81.
Article
CAS
Google Scholar
Chen C-H, et al. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2011;15(01):77–90.
Article
Google Scholar
Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer’s disease. Curr Alzheimer Res. 2017;14(4):412–412.
Article
CAS
Google Scholar
Wang C, et al. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat Commun. 2022. https://doi.org/10.1038/s41467-022-29552-6.
Article
Google Scholar
Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19(R1):R12–20.
Article
CAS
Google Scholar
Selles MC, Oliveira MM, Ferreira ST. Brain inflammation connects cognitive and non-cognitive symptoms in Alzheimer’s disease. J Alzheimers Dis. 2018;64(s1):S313–27.
Article
Google Scholar
Chen W-W, Zhang X, Huang W-J. Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep. 2016;13(4):3391–6.
Article
CAS
Google Scholar
Young JK. Neurogenesis makes a crucial contribution to the neuropathology of Alzheimer’s disease. J Alzheimer’s Dis Rep. 2020;4(1):365–365.
Article
Google Scholar
Kempuraj D, et al. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.
Google Scholar
Huang X, Hussain B, Chang J. Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neurosci Ther. 2021;27(1):36–36.
Article
CAS
Google Scholar
Coelho AA, et al. Inducible nitric oxide synthase inhibition in the medial prefrontal cortex attenuates the anxiogenic-like effect of acute restraint stress via CB1 receptors. Front Psych. 2022;13:1359–1359.
Google Scholar
Di Filippo M, et al. Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis. 2010;20(s2):S369–79.
Article
Google Scholar
Calkins MJ, Manczak M, Reddy PH. Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer’s disease. Pharmaceuticals. 2012;5(10):1103–1103.
Article
CAS
Google Scholar
Picone P, et al. Mitochondrial dysfunction: different routes to Alzheimer’s disease therapy. Oxid Med Cell Longev. 2014;2014:780179–780179.
Article
Google Scholar
Wang B, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther. 2021;6(1):1–30.
Google Scholar
Rao JS, et al. Neuroinflammation and synaptic loss. Neurochem Res. 2012;37(5):903–10.
Article
CAS
Google Scholar
Julien C, et al. Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res. 2008;86(10):2292–302.
Article
CAS
Google Scholar
Popp J, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2009;43(8):749–53.
Article
Google Scholar
Rao C, Reddy B. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4(1):29–42.
Article
CAS
Google Scholar
O’Bryant SE, et al. A precision medicine model for targeted NSAID therapy in Alzheimer’s disease. J Alzheimers Dis. 2018;66(1):97–97.
Article
CAS
Google Scholar
Breitner JCS, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899–905.
Article
CAS
Google Scholar
McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639–47.
Article
CAS
Google Scholar
Zandi P. Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence. Neurobiol Aging. 2001;22(6):811–7.
Article
CAS
Google Scholar
Heneka MT, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128(Pt 6):1442–53.
Article
Google Scholar
Choi SH, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem. 2013;124(1):59–59.
Article
CAS
Google Scholar
Moore AH, et al. Non-steroidal anti-inflammatory drugs in alzheimer’s disease and Parkinson’s disease: reconsidering the role of neuroinflammation. Pharmaceuticals. 2010;3(6):1812–41.
Article
CAS
Google Scholar
Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci. 2010;2:19–19.
CAS
Google Scholar
Eriksen JL, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Investig. 2003;112(3):440–9.
Article
CAS
Google Scholar
Hershey LA, Lipton RB. Naproxen for presymptomatic Alzheimer disease. Neurology. 2019;92(18):829–30.
Article
Google Scholar
Martin B. Double placebo design in a prevention trial for Alzheimer’s disease. Control Clin Trials. 2002;23(1):93–9.
Article
Google Scholar
Barranco Quintana JL, et al. Factores de riesgo de la enfermedad de Alzheimer. Revista de Neurología. 2005;40(10):613–613.
Article
CAS
Google Scholar
Guan PP, et al. Cyclooxygenase-2 induced the β-amyloid protein deposition and neuronal apoptosis via upregulating the synthesis of prostaglandin E2 and 15-deoxy-Δ12,14-prostaglandin J2. Neurotherapeutics. 2019;16(4):1255–1255.
Article
CAS
Google Scholar
Yermakova AV, et al. Cyclooxygenase-1 in human alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol. 1999;58(11):1135–46.
Article
CAS
Google Scholar
Schatzberg Morón AF, Nemeroff CB. Tratado de psicofarmacología. Barcelona: Editorial Médica Panamericana SA; 2006.
Google Scholar
McAdam BF, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci. 1999;96(1):272–7.
Article
CAS
Google Scholar
Prasad KN, et al. Prostaglandins as putative neurotoxins in Alzheimer’s disease. Exp Biol Med. 2016;219(2):120–5. https://doi.org/10.3181/00379727-219-44323.
Article
Google Scholar
Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer’s disease. Mount Sinai J Med. 2010;77(1):69–69.
Article
Google Scholar
Chen G, et al. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer’s disease. Nature. 2000;408(6815):975–9.
Article
CAS
Google Scholar
Götz J, et al. Transgenic animal models of Alzheimer’s disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004;9(7):664–83.
Article
Google Scholar
Deters N, Ittner LM, Götz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci. 2008;28(1):137–47.
Article
Google Scholar
Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402–5.
Article
CAS
Google Scholar
Cisternas P, et al. New insights into the spontaneous human Alzheimer’s disease-like model Octodon degus: unraveling amyloid-β peptide aggregation and age-related amyloid pathology. J Alzheimers Dis. 2018;66(3):1145–63.
Article
CAS
Google Scholar
Inestrosa NC, et al. Human-like rodent amyloid-β-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol Aging. 2005;26(7):1023–8.
Article
CAS
Google Scholar
Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837–42.
Article
CAS
Google Scholar
Wilcox KC, et al. Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol. 2011;31(6):939–48.
Article
CAS
Google Scholar
Sarasa M, Pesini P. Natural non-trasgenic animal models for research in alzheimer’s disease. Curr Alzheimer Res. 2009;6(2):171–78. https://doi.org/10.2174/156720509787602834
Article
CAS
Google Scholar
Kim JH, et al. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res. 2017;41(4):435–43.
Article
Google Scholar
Brown ML, Schneyer A. A decade later: revisiting the TGFβ family’s role in diabetes. Trends Endocrinol Metab. 2021;32(1):36–47.
Article
CAS
Google Scholar
Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer’s disease: a review. Neuropsychol Rev. 2000;10(2):115–29.
Article
CAS
Google Scholar
Ríos JA, et al. Is Alzheimer’s disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol. 2014;121:125–46.
Article
Google Scholar
Sastre M, et al. Inflammatory risk factors and pathologies associated with Alzheimers disease. Curr Alzheimer Res. 2011;8(2):132–41.
Article
CAS
Google Scholar
Sims-Robinson C, et al. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6(10):551–9.
Article
CAS
Google Scholar
Zhang Q, et al. Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture. Nat Commun. 2020;11(1):4799–4799.
Article
CAS
Google Scholar
Bracko O, et al. High fat diet worsens Alzheimer’s disease-related behavioral abnormalities and neuropathology in APP/PS1 mice, but not by synergistically decreasing cerebral blood flow. Sci Rep. 2020;10(1):1–16.
Article
Google Scholar
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–96. https://doi.org/10.1016/S0140-6736(16)30054-X.
Article
Google Scholar
Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69(1):29–35.
Article
CAS
Google Scholar
Hahm JR, et al. Metabolic stress alters antioxidant systems, suppresses the adiponectin receptor 1 and induces Alzheimer’s like pathology in mice brain. Cells. 2020;9(1):249–249.
Article
CAS
Google Scholar
Caterson ID, Gill TP. Obesity: epidemiology and possible prevention. Best Pract Res Clin Endocrinol Metab. 2002;16(4):595–610.
Article
Google Scholar
Cisternas P, et al. Modulation of glucose metabolism in hippocampal neurons by adiponectin and resistin. Mol Neurobiol. 2019;56(4):3024–37.
Article
CAS
Google Scholar
Aragonès G, et al. Circulating microbiota-derived metabolites: a "liquid biopsy? Int J Obes. 2020;44(4):875–85.
Article
Google Scholar
Heger LA, et al. Inflammation in acute coronary syndrome: expression of TLR2 mRNA is increased in platelets of patients with ACS. PLoS ONE. 2019;14(10):e0224181–e0224181.
Article
CAS
Google Scholar
McDonald CL, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease. Brain Behav Immun. 2016;58:191–200.
Article
CAS
Google Scholar
Pourbadie HG, et al. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer’s disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiol Aging. 2018;70:203–16.
Article
CAS
Google Scholar
Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001;276(40):37692–9.
Article
CAS
Google Scholar
Szymańska A, et al. TLR2 expression on leukemic B cells from patients with chronic lymphocytic leukemia. Arch Immunol Ther Exp. 2019;67(1):55–65.
Article
Google Scholar
Butovsky O, et al. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol Cell Neurosci. 2005;29(3):381–93.
Article
CAS
Google Scholar
Lin J, et al. PD-1+CXCR5−CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology. 2019;58(12):2188–92.
Article
CAS
Google Scholar
Mittal K, et al. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates Alzheimer pathology. iScience. 2019;16:298–311.
Article
CAS
Google Scholar
Pabon MM, et al. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J Neuroinflammation. 2011;8:9–9.
Article
CAS
Google Scholar
Smith HJ, et al. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer. 2018;124(24):4657–66.
Article
CAS
Google Scholar
Trier N, et al. Human MHC-II with shared epitope motifs are optimal Epstein-Barr virus glycoprotein 42 ligands-relation to rheumatoid arthritis. Int J Mol Sci. 2018;19(1):317–317.
Article
Google Scholar
Ahmed Z, et al. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem. 2007;55(7):687–700.
Article
CAS
Google Scholar
de Zorzi VN, et al. Galangin prevents increased susceptibility to pentylenetetrazol-stimulated seizures by prostaglandin E2. Neuroscience. 2019;413:154–68.
Article
Google Scholar
Sillerud LO, et al. Longitudinal monitoring of microglial/macrophage activation in ischemic rat brain using Iba-1-specific nanoparticle-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab. 2020;40(1_suppl):S117–33.
Article
CAS
Google Scholar
Neri M, et al. Immunohistochemical evaluation of aquaporin-4 and its correlation with CD68, IBA-1, HIF-1α, GFAP, and CD15 expressions in fatal traumatic brain injury. Int J Mol Sci. 2018;19(11):3544–3544.
Article
Google Scholar
Qiu L-L, et al. Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca(2+)/calpain might contribute to postoperative cognitive dysfunction in aging mice. J Neuroinflammation. 2020;17(1):23–23.
Article
Google Scholar
Sakae N, et al. Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Ann Clin Transl Neurol. 2019;6(9):1782–96.
Article
CAS
Google Scholar
Salobrar-García E, et al. Microglial activation in the retina of a triple-transgenic Alzheimer’s disease mouse model (3xTg-AD). Int J Mol Sci. 2020;21(3):816–816.
Article
Google Scholar
Abdelhak A, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798–14798.
Article
CAS
Google Scholar
Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res. 2000;25(9):1439–51.
Article
CAS
Google Scholar
Kamphuis W, et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE. 2012;7(8):e42823–e42823.
Article
CAS
Google Scholar
Hagemann TL, et al. Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. Ann Neurol. 2018;83(1):27–39.
Article
CAS
Google Scholar
Iorio R, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2017;89(2):138–46.
Article
Google Scholar
Kimura A, et al. Clinical characteristics of autoimmune GFAP astrocytopathy. J Neuroimmunol. 2019;332:91–8.
Article
CAS
Google Scholar
Nichols NR, et al. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993;14(5):421–9.
Article
CAS
Google Scholar
Yue JK, et al. Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study. The Lancet Neurology. 2019;18(10):953–61.
Article
CAS
Google Scholar
Chen Y-L, et al. Serum TNF-α concentrations in type 2 diabetes mellitus patients and diabetic nephropathy patients: a systematic review and meta-analysis. Immunol Lett. 2017;186:52–8.
Article
CAS
Google Scholar
Corrado A, et al. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis. Int J Immunopathol Pharmacol. 2017;30(3):302–7.
Article
CAS
Google Scholar
Furue K, et al. Psoriasis and the TNF/IL23/IL17 axis. G Ital Dermatol Venereol. 2019. https://doi.org/10.23736/S0392-0488.18.06202-8.
Article
Google Scholar
Starkie R, et al. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J. 2003;17(8):1–10.
Article
Google Scholar
Zhang Y-Y, et al. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease. Clin Interv Aging. 2013;8:103–10.
CAS
Google Scholar
Afsar B, et al. The future of IL-1 targeting in kidney disease. Drugs. 2018;78(11):1073–83.
Article
CAS
Google Scholar
Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063–9.
Article
CAS
Google Scholar
Colton CA, et al. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation. 2006;3:27–27.
Article
Google Scholar
Herder C, et al. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab. 2015;26(10):551–63.
Article
CAS
Google Scholar
Toplak N, Blazina Š, Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Dev Ther. 2018;12:1633–43.
Article
CAS
Google Scholar
Ahmed AS, et al. NF-κB-associated pain-related neuropeptide expression in patients with degenerative disc disease. Int J Mol Sci. 2019;20(3):658–658.
Article
CAS
Google Scholar
Gao J, et al. Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimer’s disease via SIRT1/NF-κB pathway. Metab Brain Dis. 2016;31(4):771–8.
Article
CAS
Google Scholar
Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008;283(46):31315–22.
Article
CAS
Google Scholar
Plantinga TS, et al. Association of NF-κB polymorphisms with clinical outcome of non-medullary thyroid carcinoma. Endocr Relat Cancer. 2017. https://doi.org/10.1530/ERC-17-0033.
Article
Google Scholar
Soleimani A, et al. Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer. Gene. 2020;726:144132–144132.
Article
CAS
Google Scholar
Zhang F, et al. Acute hypoxia induced an imbalanced M1/M2 activation of microglia through NF-κB signaling in Alzheimer’s disease mice and wild-type littermates. Front Aging Neurosci. 2017;9:282–282.
Article
Google Scholar
Zheng L, et al. Placental expression of AChE, α7nAChR and NF-κB in patients with preeclampsia. Ginekol Pol. 2018;89(5):249–55.
Article
Google Scholar